In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands

British Journal of Pharmacology

Volumn 149, Issue 4, 2006, Pages 431-440

  Cascio, M G ^a,f   Bisogno, T ^a   Palazzo, E ^b   Thomas, A ^c   Van Der Stelt, M ^d   Brizzi, A ^e   De Novellis, V ^b   Marabese, I ^b   Ross, R ^c   Van De Doelen, T ^d   Brizzi, V ^e   Pertwee, R ^c   Maione, S ^b   Di Marzo, V ^a  

^a CNR   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NV ORGANON   (Netherlands)

^e UNIVERSITY OF SIENA   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

Author keywords

Agonist; Antagonist; Endocannabinoid; Inverse agonist; Pain; Partial agonist; Receptor

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 11 (3 HYDROXY 5 PENTYLPHENOXY)UNDECANOIC ACID CYCLOPROPYLAMIDE; 11 (5 HYDROXY 5 PENTYLPHENOXY)UNDECANOIC ACID CYCLOPROPYLAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ADENYLATE CYCLASE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CB 25; CB 52; CYCLIC AMP; CYCLOPROPANE DERIVATIVE; DIMETHYL SULFOXIDE; FORMALDEHYDE; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); OLIVETOL; RESORCINOL DERIVATIVE; RIMONABANT; UNCLASSIFIED DRUG; UNDECANOIC ACID;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BRAIN MEMBRANE; CELL MEMBRANE; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE BINDING; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT;

ACTION POTENTIALS; ADENYLATE CYCLASE; AMIDES; ANALGESICS; ANIMALS; BRAIN STEM; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); LIGANDS; MALE; MICE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RESORCINOLS; TRANSFECTION;

EID: 33750070363     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706888     Document Type: Article

References (35)

1. Beaulieu P, Bisogno T, Punwar S, Farquhar-Smith WP, Ambrosino G, Di Marzo V et al. (2000). Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol 396: 85-92.
2. Bisogno T, Sepe N, Melck D, Maurelli S, De Petrocellis L, Di Marzo V (1997). Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. Biochem J 322: 671-677.
3. Brizzi A, Brizzi V, Cascio MG, Bisogno T, Sirianni R, Di Marzo V (2005). Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. J Med Chem 48: 7343-7350.
4. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
5. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi N, Sotgiu ML et al. (2004). Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduced both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141: 4-8.
6. Costa B, Trovato AE, Colleoni M, Giagnoni G, Zarini E, Croci T (2005). Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 116: 52-61.
7. Croci T, Landi M, Galzin AM, Marini P (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122.
8. De Novellis V, Mariani L, Palazzo E, Vita D, Marabese I, Scafuro M et al. (2005). Periaqueductal grey CB1 cannabinoid and metabotropic glutamate subtype 5 receptors modulate changes in rostral ventromedial medulla neuronal activities induced by subcutaneous formalin in the rat. Neuroscience 134: 269-281.
9. Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler RL et al. (2001). Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor 'hybrid' ligands. Biochem Biophys Res Commun 281: 444-451.
10. Di Marzo V, Blumberg PM, Szallasi A (2002). Endovanilloid signaling in pain. Curr Opin Neurobiol 2: 372-379 (review).
11. Fields HL, Vanegas H, Hentall ID, Zorman G (1983). Evidence that disinhibition of brain stem neurones contributes to morphine analgesia. Nature 306: 684-686.
12. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M et al. (1999). HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233.
13. Hargreaves K, Dubner R, Brown F, Flores C, Joris J (1988). A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
14. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW et al. (2006). CB2 cannabinoid receptor mediation of antinociception. Pain 12: 36-42.
15. Iversen L, Chapman V (2002). Cannabinoids: a real prospect for pain relief? Curr Opin Pharmacol 2: 50-55 (review).
16. Iwamura H, Suzuki H, Ueda Y, Kaya T, Inaba T (2001). In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 296: 420-425.
17. Kishimoto S, Muramatsu M, Gokoh M, Oka S, Waku K, Sugiura T (2005). Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 137: 217-223.
18. Lichtman AH, Leung D, Shelton CC, Saghatelian A, Hardouin C, Boger DL et al. (2004b). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 311: 441-448.
19. Lichtman AH, Shelton CC, Advani T, Cravatt BF (2004a). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain 109: 319-327.
20. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT et al. (2006). A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 316: 780-788.
21. Mazzola C, Micale V, Drago F (2003). Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur J Pharmacol 477: 219-225.
22. Melck D, Rueda D, Galve-Roperh I, De Petrocellis L, Guzman M, Di Marzo V (1999). Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 463: 235-240.
23. Oka S, Wakui J, Gokoh M, Kishimoto S, Sugiura T (2006). Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: interference with the actions of an endogenous ligand, 2- arachidonoylglycerol. Eur J Pharmacol 538: 154-162.
24. Palazzo E, Marabese I, De Novellis V, Oliva P, Rossi F, Berrino L et al. (2001). Metabotropic and NMDA glutamate receptors participate in the cannabinoid-induced antinociception. Neuropharmacology 40: 319-326.
25. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA.
26. Pegorini S, Zani A, Braida D, Guerini-Rocco C, Sala M (2006). Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 147: 552-559.
27. Pertwee RG (2005). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76: 1307-1324 (review).
28. Straiker A, Mackie K (2005). Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501-517.
29. Sulcova E, Mechoulam R, Fride E (1998). Biphasic effects of anandamide. Pharmacol Biochem Behav 59: 347-352.
30. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. (2005). Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917-926.
31. Tortorici V, Morgan MM (2002). Comparison of morphine and kainic acid microinjections into identical PAG sites on the activity of RVM neurons. J Neurophysiol 88: 1707-1715.
32. Ueda Y, Miyagawa N, Matsui T, Kaya T, Iwamura H (2005). Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 520: 164-171.
33. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D et al. (2006). Dual role of brain endocannabinoids in experimental models of Alzheimer's disease. Cell Mol Life Sci 63: 1410-1424.
34. Vigano D, Rubino T, Vaccani A, Bianchessi S, Marmorato P, Castiglioni C et al. (2005). Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems. Psychopharmacology 182: 527-536.
35. Walker JM, Huang SM, Strangman NM, Tsou K, Sanudo-Pena MC (1999). Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96: 12198-12203.